leadf
logo-loader
viewAIM ImmunoTech Inc

AIM ImmunoTech Inc: Meet the team behind the drug that put a 90% dent in COVID-19 infection

Join AIM ImmunoTech, Heat Biologics, Avalon GloboCare, Oregenisis, and ImmunoPrecise Antibodies via the Proactive One2One Investor Forum, September 10, 1pm EDT.

Orgenesis - AIM ImmunoTech Inc: Meet the team behind the drug that put a 90% dent in COVID-19 infection

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) is one of five biopharma companies presenting at Proactive’s online event on September 10 – all of them are playing a role to combat COVID-19.

The event kicks off at 1 pm EDT on Thursday, September 10.

This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses.

SIGN-UP: Proactive One2One September 10

Florida-based AIM ImmunoTech has ordinarily focussed on the research into the treatment of immune disorders, and it has developed the drug Ampligen which according to a study can decrease the infectious viral yield of SARS-CoV-2 by 90% (in a recent in vitro model).

The company has decided to test Ampligen in humans – a trial is slated to begin patient enrolment at Roswell Park cancer center soon (it will examine Ampligen in combination with interferon alfa-2b in cancer patients with COVID-19).

Ampligen has also been shipped to Japan where it will be used in a test as a potential vaccine adjuvant for COVID-19.

The other companies on Thursday’s roster include Heat Biologics Inc (NASDAQ:HTBX), Avalon GloboCare Corp (NASDAQ:AVCO), Oregenisis Inc (NASDAQ:ORGS), ImmunoPrecise Antibodies Ltd (CVE:IPA, OTCQB:IPATF).

Quick facts: AIM ImmunoTech Inc

Price: 2.06 USD

NYSE:AIM
Market: NYSE
Market Cap: $81.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AIM ImmunoTech Inc named herein, including the promotion by the Company of AIM ImmunoTech Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

AIM Immunotech forms Phase 1/2a clinical trial agreement to fight the...

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) CEO Tom Equels tells Proactive that it has struck a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support its Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with the coronavirus. What's...

on 07/20/2020

2 min read